Prof. Bibekanand Mallick

About

Prof. Bibekanand Mallick is a Fellow of the National Academy of Biological Sciences (FNABS), Royal Society of Biology, London (FRSB), and a Member of the National Academy of Sciences, India (NASI). He is the editor of reputed SCI journals, including Experimental Cell Research and Communications Biology (Nature portfolio journal). He was recently honoured with the NABS Best Scientist Award in Basic Sciences. Prof. Mallick leads the RNAi Laboratory at the National Institute of Technology Rourkela and conducts a wide range of research in molecular biology in cancer. He is known for his research on RNA interference, gene silencing, drug repurposing, and RNAi therapeutics for cancer. He has discovered a small RNA that potentially suppresses tumorigenesis and reduces chemotherapy resistance in cancers, especially tongue cancer. He is also the author of several books published by renowned publishers like Oxford University Press, McGraw Hill, Springer, and Elsevier, USA.

Employment

• National Institute of Technology Rourkela Professor
  2024 - Present
• National Institute of Technology Rourkela
  2009 - Present
• New York State Department of Health - Wadsworth Center
  2009 - 2011

Education

• Indian Association for the Cultivation of Science PhD
  2003 - 2008

Projects & Funding

Projects & funding information is unavailable.

Publications (96)

• Integrated omics and virtual screening predict Tabularin as a dual inhibitor of the prognostic microRNAs mir-19a and mir-32 in colorectal cancer
  Computational Biology and Chemistry 2026 DOI: 10.1016/j.compbiolchem.2026.109211
  +Save
• KLF5-mediated transcriptional activation of miR-203a inhibits EMT and increases cisplatin sensitivity by targeting SNAI2 in tongue cancer
  Archives of Biochemistry and Biophysics 2026 DOI: 10.1016/j.abb.2026.110845
  +Save
• microRNA-203a-3p sensitizes cisplatin through disruption of RAN-dependent RRM2 nuclear localization and mitochondrial stress readouts
  Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms 2026 DOI: 10.1016/j.bbagrm.2026.195166
  +Save
• Cisplatin disrupts OCT1-DNMT1-piRNA epigenetic regulatory axis to suppress GAB2-mediated aggressiveness in OSCC
  Archives of Biochemistry and Biophysics 2026 DOI: 10.1016/j.abb.2026.110756
  +Save
• Projection of epigenetic markers of Type 2 Diabetes Reveal Pancreatic Cancer Prognostic Tumour States
  2026 IEEE International Conference for Convergence in Computing Technology (I3CTCON) 2026 DOI: 10.1109/i3ctcon68242.2026.11507248
  +Save
• Strategies for dissecting the PIWI–piRNA–DNMT axis: Epigenetic silencing mechanisms underlying tumorigenesis
  Methods in Enzymology 2026 DOI: 10.1016/bs.mie.2026.07.027
  +Save
• Targeting EGFR in cancer using Terminalia arjuna: An integrated In Silico, molecular dynamics, experimental validation, and network pharmacology study
  Computational Biology and Chemistry 2026 DOI: 10.1016/j.compbiolchem.2026.109336
  +Save
• PLK1 inhibition by Shikonin attenuates oral cancer growth through β-catenin-mediated regulation of EMT and apoptosis.
  Cellular signalling 2025 DOI: 10.1016/j.cellsig.2025.112262
  +Save
• Silent Guardians Gone Rogue: The Role of PIWI and piRNA in Malignant Transformation
  IUBMB Life 2025 DOI: 10.1002/iub.70077
  +Save
• A piRNA chemosensitizes doxorubicin in tongue squamous cell carcinoma by targeting FDFT1 and inhibiting the EIF3H/HIF1α/CYPOR axis
  Archives of Biochemistry and Biophysics 2025 DOI: 10.1016/j.abb.2025.110455
  +Save